Author’s response to reviews

Title: Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial

Authors:

Yongxia Wang (wyxchzhq@163.com)
Xinlu Wang (wangxinlu110@126.com)
Jianru Wang (1016052609@qq.com)
Bin Li (libinnvhai@163.com)
Rui Yu (betterme0107@sina.com)
Yucai Hu (huyucai911@163.com)
Xingyuan Li (1096020387@qq.com)
Guangcao Peng (pengguangcao@163.com)
Mengmeng Zhang (2512940129@qq.com)
Mingjun Zhu (zhumingjun317@163.com)

Version: 2 Date: 24 Feb 2020

Author’s response to reviews:

Item 27: Perhaps you could state how you will store information to ensure confidentiality. Verify that data collected during the course of the research will be kept strictly confidential and only accessed by members of the trial team (or individuals from the Sponsor organisation or centre sites where relevant to the trial). Will participants be allocated an individual trial identification number and will participant’s details will be stored on a secure database? Who will access rights to the data set? Will anonymised trial data be shared with other researchers to enable international prospective meta-analyses?

Above all, all of the data collected during the course of the research will be kept strictly confidential, all of the participants be allocated an individual trial identification number and only accessed by members of the trial team. Of course, all of the anonymised trial data will be shared with other researchers to enable international prospective meta-analyses.

2. I also wanted to ask you about the information in the form you completed when you submitted – it states “Yes, the funding is external and not industry funded, and I have included the relevant documentation as an additional file.” Yet some of the funding is from Tianjin Zhongxin Pharmaceutical Group Co., Ltd – so there is industry funding.
This work is supported by the Ministry of Science and Technology of the People’s Republic of China’s Key Projects during the 13th Five-Year Plan Period (No. 2018YFC1707402, No. 2019YFC1710000, E-mail: cncbd@cncbd.org.cn). In addition, we are also supported by the Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Le Ren Tang Pharmaceutical Factory, including industry funded. China’s Ministry of Science and Technology and Tianjin Zhongxin Pharmaceutical Group Co., Ltd., Le Ren Tang Pharmaceutical Factory, did not take part in the design of this study and will not have any role during its execution, analysis, or data interpretation or in the decision to submit results. All of the money supplied by companies will be used only to pay for the materials.